Kiniksa Pharmaceuticals

14d ago, source: Forbes

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating ...

Kiniksa Pharmaceuticals Ltd Class A

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

17d ago, source: Yahoo Finance

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating ...

Kiniksa to launch Phase 2b Sjogren’s Disease trial in 2H 2024

16d ago, source: Investing

HAMILTON, Bermuda - Kiniksa Pharmaceuticals, Ltd. (NASDAQ: NASDAQ:KNSA), a biopharmaceutical company, announced today its intention to begin a Phase 2b clinical trial for abiprubart in patients ...

Kiniksa Pharmaceuticals Provides Corporate Update

29d ago, source: ADVFN

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and ...

Kiniksa Pharmaceuticals Ltd. Registered Shs A BE-,000273235 Aktie

22d ago, source: Finanzen100

Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

16d ago, source: Stockhouse

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets ...

KNSA Kiniksa Pharmaceuticals, Ltd.

1mon ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Kiniksa to launch Phase 2b Sjogren’s Disease trial in 2H 2024

16d ago, source: Investing

HAMILTON, Bermuda - Kiniksa Pharmaceuticals, Ltd. (NASDAQ: NASDAQ:KNSA), a biopharmaceutical company, announced today its intention to begin a Phase 2b clinical trial for abiprubart in patients with ...

Kiniksa Pharmaceuticals Ltd.

7d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

16d ago, source: Business Insider

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and ...